Influence of domperidone supplementation on short‐term changes in C‐reactive protein and paraoxonase‐1 in dogs with leishmaniasis undergoing meglumine antimoniate and allopurinol therapy

Abstract

BackgroundC‐reactive protein (CRP) and paraoxonase 1 (PON1) might increase and decrease in canine leishmaniasis (CanL), , and both can rapidly normalize after therapy. Recently, supplementation of domperidone with conventional therapy , increasing the activity of cells involved in acute phase responses in vitro. This combined therapy has been recommended to treat mild forms of CanL; however, no studies have investigated the effects of domperidone supplementation on early CRP or PON1 changes in dogs with CanL.ObjectivesThe aim of this study was to evaluate whether domperidone, added to conventional treatments, modifies CRP concentration and PON1 activity kinetics in CanL dogs responsive to conventional therapy.MethodsSerum CRP concentrations and PON1 activities were measured in dogs with mild CanL before (t‐0) and 3 (t‐1), 7 (t‐2), 14 (t‐3), and 21 (t‐4) days after treatment with N‐methylglucamine antimoniate and allopurinol alone (n = 18) or combined with domperidone (n = 18).ResultsC‐reactive protein concentrations increased at t‐1 in the domperidone group, especially when the CRP concentration at t‐0 was normal. However, the concentrations normalized at t‐4 in 18/18 dogs compared with 14/18 dogs not receiving domperidone. The median PON1 activity decreased at t‐1 in the domperidone group, and this decrease was more significant in dogs with normal PON1 activity at t‐0.ConclusionsBased on these results, transient increases in CRP concentrations or decreases in PON1 activities after domperidone administration should not be erroneously interpreted as signs of a worsening disease process.

Effect of domperidone (leisguard®) on antibody titers, inflammatory markers and creatinine in dogs with leishmaniosis and chronic kidney disease

“…Therefore, based on the considerations outlined above, the primary aim of this study was to evaluate the efficacy of domperidone (leisguard®; Ecuphar Italia srl, Milan, Italy) in: (i) maintaining and/or improving renal function (stable or decreased serum creatinine [SC]) and (ii) maintaining and/or reducing proteinuria (stable or decreased urinary protein/creatinine ratio [UPC]), in dogs with leishmaniosis affected by CKD. Moreover, in order to confirm previous published data [ 19 , 20 , 30 ], we also investigated the effect of leisguard® on serum antibody titers for L. infantum and on the concentrations of globulins, gamma globulins, C-reactive protein (CRP) and big endothelin-1 (big ET-1) in dogs with leishmaniosis.…”

C-Reactive Protein as a Diagnostic Marker in Dogs: A Review

“…The finding that canine leishmaniasis doesn’t always result in changes in WBC is very important in a clinical setting, where CRP could be the only parameter suggesting an inflammation caused by the parasite [ 48 ]. However, when it comes to the treatment of this disorder, the CRP changes should be interpreted with caution [ 71 ]. Similarly, Neospora caninum invasion could influence APR leading to an increase in the concentration of APPs [ 12 ].…”